Lilly Limits Zyprexa Sales as 340B Price Falls to a Penny

by Admin | April 4, 2012 9:28 am

April 4, 2012—Drug manufacturer Eli Lilly and Co. is limiting sales of its widely used atypical antipsychotic Zyprexa (olanzapine) in light of the drug’s 340B ceiling price falling to $0.01 under the Office of Pharmacy Affairs’ (OPA) “penny pricing” policy.

The company notified OPA that it was instituting the purchasing limits in a March 28 letter[1] that OPA posted on its home page on April 2. It marks the first time that a manufacturer has announced an allocation system for one of its products since OPA clarified its penny-pricing policy[2] last November. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[3].    Already registered? Click here to login[4]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

Endnotes:
  1. a March 28 letter: http://www.hrsa.gov/opa/docs/Zyprexa_Limited_Distribution_OPEN_Letter_to_HRSA_(March_28__2012).pdf
  2. since OPA clarified its penny-pricing policy: http://www.hrsa.gov/opa/Docs/PolicyReleasePennyPricing.pdf
  3. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  4. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2012/04/lilly-limits-zyprexa-sales-as-340b-price-falls-to-a-penny/

Copyright ©2025 340binformed.org unless otherwise noted.